About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Depression Clinical Trials in Philadelphia | 174 Studies

Clinical Trials DepressionPhiladelphia

Depression Clinical Trials in Philadelphia

Find 174 clinical trials for depression near Philadelphia, Pennsylvania. Connect with research centers in your area.

All Depression trials nationwide All trials in Philadelphia

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 1-20 of 174 trials

WithdrawnVortioxetine in Patients With Major Depressive Disorder and Coronary Artery DiseaseThis is a preliminary, open-label, clinical trial designed to assess the efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in…NCT02454426·Philadelphia, Pennsylvania Active not recruiting"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"The purpose of this study is to examine the efficacy, safety, and tolerability of CYB003 compared to matching placebo as adjunctive treatment in participants with MDD.NCT06564818·Phoenix, Arizona and 44 others

Depression Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix San Antonio

Data from ClinicalTrials.govTerms

CompletedEfficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in Combination With an Antidepressant in the Treatment of Major Depressive DisordersThe purpose of this study is to evaluate the efficacy of quetiapine SR in combination with an antidepressant versus an antidepressant alone in patients with MDD with inadequate…NCT00326105·Phoenix, Arizona and 55 others

TerminatedExtension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant TreatmentTo assess the safety and tolerability of long-term pimavanserin treatment in subjects with major depressive disorder and inadequate response to antidepressant treatment.NCT04000009·Garden Grove, California and 70 others

CompletedSynchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive DisorderThis study is designed to evaluate the safety and efficacy of synchronized transcranial magnetic stimulation (sTMS) using the NeoSync EEG Synchronized TMS device (NEST) in…NCT01370733·Los Angeles, California and 17 others

CompletedTreatment for Depressed, Obese Individuals at Risk for Cardiovascular Disease (CVD)To determine whether individuals who suffer from depression and obesity are able to lose weight and show improvements in mood and cardiovascular disease risk factors following 20…NCT01692574·Philadelphia, Pennsylvania

RecruitingTaking Action for College StudentsThe goal of this research is to investigate whether a peer-delivered illness self-management program called Taking Action can help college students with serious mental illnesses.NCT06700902·Philadelphia, Pennsylvania

CompletedStudy to Evaluate Potential Predictors of Relapse in Participants With Major Depressive Disorder (MDD)The purpose of this study is to identify if there are self-reported or objective measures related to mood parameters that can predict near-term relapse (within 1 month or at…NCT02489305·Birmingham, Alabama and 24 others

CompletedA Long-Term Safety Study of ALKS 5461This is a 52-week open-label study to evaluate the safety and tolerability of ALKS 5461.NCT02141399·Birmingham, Alabama and 157 others

CompletedTreatments for Depression: Drug Versus PsychotherapyThis 4-8 month study, with a 2-year follow up period, will compare sertraline (Zoloft®), venlafaxine (Effexor®), supportive-expressive psychotherapy, and placebo to determine…NCT00043550·Philadelphia, Pennsylvania

CompletedAntidepressant Therapy in Treating Bipolar Type II Major DepressionThis study will compare the safety and effectiveness of antidepressant therapy versus mood stabilizing therapy in treating people with bipolar type II major depression.NCT00602537·Philadelphia, Pennsylvania

RecruitingNBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.NCT06963021·Chino, California and 34 others

CompletedSafety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)To assess the long-term safety and tolerability of oral OPC-34712 (brexpiprazole), given in addition to an FDA approved antidepressant (ADT) for the treatment of adults with Major…NCT01360866·Birmingham, Alabama and 141 others

TerminatedStudy to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)This will be a multicenter, randomized, double-blind study designed to assess the efficacy, safety and tolerability of an oral Aripiprazole/Escitalopram combination therapy in…NCT01111565·Tucson, Arizona and 52 others

CompletedGenomics Used to Improve DEpression DecisionsEvaluate the impact of GeneSight Psychotropic on response to psychotropic treatment as judged by the mean change in the 17-item Hamilton Depression (HAM-D17) score from baseline…NCT02109939·Birmingham, Alabama and 60 others

RecruitingTriage Survey for Psychiatry Research EligibilityTRIAGE-Psych is a survey study designed to assess potential participants' eligibility to screen for industry-sponsored psychiatry clinical trials.NCT05800925·Boston, Massachusetts and 5 others

CompletedA Study of CX157 (TriRima) for the Treatment of DepressionThe purpose of this study is to examine the efficacy of CX157 60 mg administered three times a day (180 mg daily dose) as compared to placebo in subjects with Major Depressive…NCT00739908·Birmingham, Alabama and 13 others

CompletedAdjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant TreatmentTo evaluate the efficacy and safety of adjunctive pimavanserin compared to placebo in subjects with major depressive disorder who have an inadequate response to antidepressant…NCT03968159·Birmingham, Alabama and 84 others

CompletedEfficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive DisorderThe purpose of this study is to evaluate the effects of Lu AA21004, once daily (QD), on cognitive dysfunction in patients with major depressive disorder.NCT01564862·Tucson, Arizona and 91 others

CompletedEfficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder (MDD)The study will assess efficacy, safety and tolerability of 0.5 mg/day and 1 mg/day of sublingual (under the tongue) formulation of agomelatine in patients with Major Depressive…NCT01110902·Birmingham, Alabama and 44 others

Page 1 of 9Next

Other Conditions in Philadelphia

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia